Avanir To File Neurodex NDA For Pseudobulbar Affect By End Of 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Avanir could see action on its upcoming Neurodex NDA for the treatment of pseudobulbar affect by mid-2005; the firm plans to submit the application by the end of the year and will request priority review.